ADC Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Revenue	69.56	209.91	33.92	0	2.34	1.14
Revenue Growth (YoY)	-66.86%	518.89%	-	-	105.26%	-
Cost of Revenue	2.53	3.3	1.39	0	0	0
Gross Profit	67.03	206.61	32.52	0	2.34	1.14
Selling, General & Admin	105.89	143.49	136.24	77.23	14.2	8.77
Research & Development	127.13	186.46	158	142.03	107.54	118.31
Operating Expenses	233.02	329.95	294.24	219.26	121.74	127.08
Operating Income	-165.99	-123.34	-261.72	-219.26	-119.4	-125.94
Interest Expense / Income	46.33	36.73	18.34	4.93	0.16	0
Other Expense / Income	-11.36	-3.17	-28.56	21.77	-3.65	-3.07
Pretax Income	-200.95	-156.9	-251.51	-245.96	-115.9	-122.87
Income Tax	39.11	0.23	-21.48	0.33	0.58	0.22
Net Income	-240.05	-157.13	-230.03	-246.29	-116.48	-123.1
Shares Outstanding (Basic)	82	78	77	71	67	-
Shares Outstanding (Diluted)	82	78	-	-	-	-
Shares Change	4.55%	1.84%	8.21%	6.04%	-	-
EPS (Basic)	-2.94	-2.01	-3.00	-3.77	-2.36	-2.64
EPS (Diluted)	-2.94	-2.01	-3.00	-3.77	-2.36	-2.64
Free Cash Flow	-121.9	-139	-230.93	-168.85	-122.8	-123.17
Free Cash Flow Per Share	-1.49	-1.78	-3.01	-2.38	-1.84	-
Gross Margin	96.36%	98.43%	95.89%	-	100.00%	100.00%
Operating Margin	-238.63%	-58.76%	-771.65%	-	-5102.52%	-11047.46%
Profit Margin	-345.11%	-74.86%	-678.20%	-	-4977.95%	-10797.89%
Free Cash Flow Margin	-175.25%	-66.22%	-680.85%	-	-5247.74%	-10804.56%
EBITDA	-151.36	-117.78	-230.54	-239.07	-114.1	-122.13
EBITDA Margin	-217.60%	-56.11%	-679.70%	-	-4876.07%	-10713.33%
Depreciation & Amortization	3.27	2.39	2.63	1.97	1.65	0.74
EBIT	-154.62	-120.17	-233.17	-241.04	-115.75	-122.87
EBIT Margin	-222.29%	-57.25%	-687.46%	-	-4946.41%	-10778.25%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).